Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
11/2003
11/06/2003WO2003090717A1 Process of forming and modifying particles and compositions produced thereby
11/06/2003WO2003090716A1 Prevention of myocardial infarction induced ventricular expansion and remodeling
11/06/2003WO2003090715A2 Particulate materials
11/06/2003WO2003090714A1 Method for the production of crystals, crystals obtained by said method, and use thereof in pharmaceutical formulations
11/06/2003WO2003090713A1 Helium propellant composition for use with aerosols
11/06/2003WO2003090712A2 Compositions for treating hyperemia
11/06/2003WO2003090711A1 Compositions and methods for sublingual formulations of dihydroergotamine for the treatment of migraine
11/06/2003WO2003090710A1 Lapachone delivery systems, compositions and uses related thereto
11/06/2003WO2003090699A1 Cosmetic composition for promoting hair growth and/or preventing or delaying hair loss
11/06/2003WO2003090693A2 Pharmaceutical composition containing lamotrigine particles of defined morphology
11/06/2003WO2003090692A2 Make-up applicator with led light source
11/06/2003WO2003090684A2 Polymer compositions containing a macrocyclic triene compound
11/06/2003WO2003090682A2 Treatment and prevention of pulmonary conditions
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003090640A2 Microbial cellulose wound dressing for treating chronic wounds
11/06/2003WO2003090599A2 Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
11/06/2003WO2003090547A1 A composition comprising waxy acids for effecting serum cholesterol levels
11/06/2003WO2003080112A3 Imidazoquinolineamines as adjuvants in hiv dna vaccination
11/06/2003WO2003079981A3 Bioadhesive drug delivery system
11/06/2003WO2003072025A3 Modified release formulations of at least one form of tramadol
11/06/2003WO2003061557A3 Levothyroxine pharmaceutical compositions, methods of making and methods of administration
11/06/2003WO2003060799A3 Compositions for treatment of central nervous system neoplasms, and methods of making and using the same
11/06/2003WO2003059193A3 Use of nanoparticles as carriers for biocides in ophthalmic compositions
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003039727A3 Apparatus and method for manufacturing encapsulated products
11/06/2003WO2003034975A3 Method for ultrasound triggered drug delivery using hollow microbubbles with controlled fragility
11/06/2003WO2003034900A3 Sterile, breathable patch for treating wound pain
11/06/2003WO2003032815A3 Medical device for delivering patches
11/06/2003WO2003028624A3 Levothyroxine compositions and methods
11/06/2003WO2003026589A3 Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
11/06/2003WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
11/06/2003WO2003015531A3 Pharmaceutical formulation containing dye
11/06/2003WO2003013428A3 Nutritional supplements and methods of using same
11/06/2003WO2003011421A3 Emulsifier mixture
11/06/2003WO2003000294A8 Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
11/06/2003WO2003000177A3 Stable controlled release pharmaceutical compositions containing pravastatin
11/06/2003WO2002102298A3 Process for the preparation of dispersions
11/06/2003WO2002094845A3 Method for stabilising of nucleic acids
11/06/2003WO2002085328A3 Method for producing an active ingredient concentrate, and an active ingredient concentrate
11/06/2003WO2002072600A3 Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
11/06/2003WO2002072100A3 Pharmaceutical composition containing pde v inhibitors and surfactants
11/06/2003WO2002069993A8 Pharmaceutical composition made of cannabis extracts
11/06/2003WO2002055020A9 Topical testosterone formulations and associated methods
11/06/2003WO2002040039A3 In vivo use of water absorbent polymers
11/06/2003WO2002038208A9 Device and method for the cessation of smoking
11/06/2003WO2002024891A9 B7-like molecules and uses thereof
11/06/2003WO2002003848A8 Method for opening the blood-brain barrier
11/06/2003WO2002002096A8 Oral compositions comprising host-response modulating agent
11/06/2003WO2002000182A8 Structures and compositions increasing the stability of peroxide actives
11/06/2003WO2001080633A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003WO2000023569A8 Surfactant protein d for the prevention and diagnosis of pulmonary emphysema
11/06/2003US20030208184 Includes lightweight, inert housing which contains infusate, and an enclosed, gas-impermeable variable volume chamber with pressure source (propellant or mechanical spring); drug delivery
11/06/2003US20030208149 Comprises collagen matrix
11/06/2003US20030208096 Method for delivering radiation to an intraluminal site in the body
11/06/2003US20030208064 Soaking a crude hydrocolloid dispersed in water to hydrate, stirring to obtain a homogenous particulate-containing sol, centrifuging to remove particulates to produce a clarified sol; filtration and recovering; foods; drugs; cosmetics
11/06/2003US20030207978 Drug delivery; improved refractive index, transparency to light, reflection, permeability, coercivity, magnetic hystereisis, breakdown voltage, biocompatability, and wear resistance
11/06/2003US20030207977 Drug delivery; improved refractive index, transparency to light, reflection, permeability, coercivity, magnetic hysteresis, breakdown voltage, biocompatability, and wear resistance
11/06/2003US20030207976 Thermal properties modified by powder size; whisker type fillers; drug delivery
11/06/2003US20030207975 Improved wear resistance/biocompatibility
11/06/2003US20030207946 Also comprises electrokinetic stabilizer such as lysine, arginine or histidine, mono-/di-ethanolamine, sodium (bi)carbonate, tromethamine and/or sodium phosphate
11/06/2003US20030207936 Comprises fatty ester modified-polyoxyethylene glycol solubilizers
11/06/2003US20030207918 Administering to patient a bolus injection of an active drug, in particular tirofiban, in an amount of 25 mu g/kg, and administering to the patient, after the bolus injection, an intravenous infusion for a period of 12-72 hours of the drug
11/06/2003US20030207907 Deliverying antirestenoic compound such as an antiproliferative, immunosuppressive, or antiinflammatory drug, particularly rapamycin, tacrolimus, paclitaxel, dexamethasone, or an active analog or derivative thereof
11/06/2003US20030207904 Sensory nerve receptor agonist for topical delivery to the human lips, mouth, and to the anorectal area
11/06/2003US20030207903 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for sexual disfunction
11/06/2003US20030207852 Treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment.
11/06/2003US20030207851 Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207797 Glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful
11/06/2003US20030207772 Warming and nonirritating lubricant compositions and method of comparing irritation
11/06/2003US20030207112 A pigment with modified properties because of the powder size being below 100 nanometers. Blue, yellow and brown pigments are illustrated. Nanoscale coated, un-coated, whisker inorganic fillers are included. Stoichiometric and
11/06/2003US20030206993 Formed by cooling to brittleness; grinding to powder; mixing with supplement; granulation; and forming tablets
11/06/2003US20030206978 Formed by spray drying; especially herbal extracts
11/06/2003US20030206971 Aqueous acidulant part comprising an activator acid, a rheology modifier or a pseudoplastic thickener, a chlorine dioxide stable visual indicator system; alkali metal chlorite
11/06/2003US20030206970 Ophthalmic compositions containing galactomannan polymers and borate
11/06/2003US20030206966 Methods of inducing apoptosis and modulating metalloproteinases
11/06/2003US20030206961 Production of purified, parenterally administrable starch by washing to remove surface-localized proteins, lipids and endotoxins; and effecting molecular weight reduction by acid hydrolysis
11/06/2003US20030206960 Delivery of microparticle-conjugated drugs for inhibition of stenosis
11/06/2003US20030206959 Method for preparing submicron particle suspensions
11/06/2003US20030206958 Chitosan biopolymer for the topical delivery of active agents
11/06/2003US20030206957 Orally administered medicament delivery systems
11/06/2003US20030206956 Topical treatment of prevention of ocular infections
11/06/2003US20030206955 Oil-in-water; nonionic and/or anionic amphiphilic lipid; anionic polymer which contains at least one hydrophobic chain; weight ratio of the amount of oily phase to the amount of amphiphilic lipid ranges from 1.2 to 10.
11/06/2003US20030206954 Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
11/06/2003US20030206953 Controlled-release preparations which can rapidly release 99% or more of a slightly soluble medicament (which by itself shows a slow dissolution rate) in the upper part of the small intestine
11/06/2003US20030206952 In a matrix with a hydrophilic polymer that is high molecular weight polyethylene oxide, hydroxypropylmethyl cellulose, or hydroxypropyl cellulose.
11/06/2003US20030206951 At least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours.
11/06/2003US20030206950 Process for the preparation of granular and porous sucralfate dry gel
11/06/2003US20030206949 Dispersible phospholipid stabilized microparticles
11/06/2003US20030206948 Having syrup components and fat or wax components and optionally fillers.
11/06/2003US20030206947 Low viscosity hydroxypropylcellulose with an average molecular weight of 30,000-100,000 and with a molar degree of substitution of at least 3
11/06/2003US20030206946 Methods for therapy of connective tissue disease
11/06/2003US20030206945 Sticking plaster for controlled release of natural interferon
11/06/2003US20030206943 Lotion is applied to a portion of the body facing surface of the topsheet that has a level of hydrophobicity equal or greater than that of said topsheet.
11/06/2003US20030206942 Fast dissolving orally consumable films containing an antitussive and a mucosa coating agent
11/06/2003US20030206941 Fast dissolving orally consumable films
11/06/2003US20030206939 Treating and/or preventing dental caries and/or tooth erosion, dental sensitivity, mouth odor, osteoporosis, calculus formation or gingivitis; recrystallising and/or remineralising enamel and/or dentine; buffering plaque
11/06/2003US20030206930 Soft gelatin capsule manufacture
11/06/2003US20030206929 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides
11/06/2003US20030206910 Poloxamer 188, Poloxamer 237, Poloxamer 338, Poloxamer 124, Poloxamer 401, Tetronic 904, Tetronic 908, Tetronic 1107 or Tetronic 90R4; especially for treating chronic hepatitis and cancer
1 ... 2071 2072 2073 2074 2075 2076 2077 2078 2079 2080 2081 2082 2083 2084 2085 2086 2087 2088 2089 2090 2091 ... 2991